FY2028 Earnings Forecast for AUTL Issued By William Blair

Autolus Therapeutics plc (NASDAQ:AUTL) – Research analysts at William Blair issued their FY2028 earnings per share estimates for Autolus Therapeutics in a research report issued on Thursday, March 20th. William Blair analyst M. Phipps anticipates that the company will earn ($0.18) per share for the year. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million.

Other research analysts also recently issued research reports about the stock. Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $9.52.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock opened at $1.62 on Monday. The business has a 50-day simple moving average of $2.00 and a 200-day simple moving average of $2.87. Autolus Therapeutics has a one year low of $1.56 and a one year high of $6.48. The company has a market cap of $431.07 million, a PE ratio of -1.34 and a beta of 2.07.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in shares of Autolus Therapeutics during the 4th quarter worth approximately $26,000. Barclays PLC boosted its stake in Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after acquiring an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth about $35,000. Arkadios Wealth Advisors acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth about $47,000. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at about $51,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.